GLP-1 Voices Worth Following in Europe: A Country-by-Country Guide

Search for the most notable GLP-1 influencers in Europe and the first results are almost all the same thing: before-and-after accounts, weekly weigh-ins, a pharmacy discount code in the caption. Those accounts have real reach. They are also, increasingly, the ones European regulators are fining, because prescription weight-loss drugs cannot be advertised to the public anywhere in the EU, the EEA or the UK. So the honest answer to “who should I follow” is not the loudest account. It is the quieter layer of doctors, researchers, journalists and patient organisations who explain these drugs instead of selling them.

This guide maps that layer, country by country. It is a companion to our complete guide to fiber and GLP-1 medications, which covers the side effects these voices spend most of their time talking about, down to the practical question of whether you can take fiber alongside the injection. Here the subject is the people themselves: who is worth your attention in each major European market, what they actually publish, and the single legal rule that explains why the scene looks the way it does.

Two things shape everything below, so they are worth stating up front.

The law is the same everywhere, and it is strict. Article 88 of EU Directive 2001/83/EC obliges every member state to ban advertising prescription-only medicines to the general public.¹ The UK keeps the identical rule after Brexit under the Human Medicines Regulations 2012.² The prohibition is on the act of advertising, not on who does it, so a patient posting a “use my code for £40 off” video is caught exactly as a company would be. The EU’s 2023 to 2026 pharmaceutical-law reform keeps this ban unchanged.³

The biggest accounts are often the ones in trouble. In February 2026 the UK Advertising Standards Authority ruled against a set of online pharmacies and named the individual influencers whose referral-code posts promoted the drugs, directing both to stop.⁴ Sweden’s medicines agency issued a marketing prohibition against the digital weight clinic Yazen with a fine of 750,000 kronor per breach.⁵ In the Netherlands the medicines inspectorate has gone further and fined national newspapers for GLP-1 coverage a court agreed read as promotional.⁶ Reach and credibility are not the same signal here. Often they point in opposite directions.

With that in mind, here is who is actually worth following.

United Kingdom

The UK has the busiest GLP-1 conversation in Europe and the most aggressive enforcement, which has quietly cleared the field. The credible voices are clinicians and authors, not journey accounts.

Dr Karan Rajan is the widest-reaching medical communicator in the country, an NHS surgeon whose myth-busting shorts run across TikTok, Instagram and YouTube to an audience his own site puts above ten million.⁷ His GLP-1 videos are explainers, not endorsements. Dr Idrees Mughal (“Dr Idz”), a doctor with a master’s in nutritional research and a book, Saturated Facts, occupies a similar debunking lane.⁸ Dr Jack Mosley, a GP and son of the late Michael Mosley, wrote Food Noise specifically about weight-loss medications and smart nutrition, and works the podcast circuit around it.⁹

For the science rather than the social feed, Prof Naveed Sattar of the University of Glasgow is the most-quoted UK researcher on cardiometabolic GLP-1 effects, and Prof Giles Yeo of Cambridge, a broadcaster and author, gives careful public lectures on what a post-Ozempic world does and does not mean.¹⁰¹¹ The most-read first-person UK account of the drugs is not a health creator at all but the author Johann Hari, whose book Magic Pill documents his own semaglutide use and reports the upside and the risks together.¹² Hari has a contested journalistic record from over a decade ago, which is worth knowing before you treat the book as neutral.

Two patient-side voices matter. Georgie Aldous, a beauty influencer hospitalised after five months on Mounjaro bought through an online questionnaire, has become a campaigner for mandatory checks and a ban on sponsored posts, which is a more useful thing to amplify than any transformation reel.¹³ The charity Obesity UK is the established patient organisation.¹⁴

A note on the journey accounts. The largest UK “what I eat in a day on Mounjaro” creators are precisely the accounts the ASA named in its February 2026 rulings for carrying pharmacy referral codes.⁴ The regulator’s own 2026 enforcement report found that paid ads had largely fallen into line, and that influencer and affiliate content was now the residual risk.¹⁵ Follow them for a sense of the culture if you must. Do not treat a discount code as medical guidance.

Ireland

Ireland’s scene is smaller and clinician-led. Enforcement runs through the HPRA and is mostly unpublished, so there is no equivalent of the ASA’s named-and-shamed list.¹⁶

Prof Donal O’Shea, the HSE’s national clinical lead for obesity and a consultant endocrinologist, is the country’s most prominent broadcast voice and a consistent critic of celebrity-driven demand.¹⁷ Prof Carel le Roux of University College Dublin is one of Europe’s leading obesity-medicine researchers and a frequent podcast guest; he discloses pharmaceutical advisory roles, which is the right way to do it.¹⁸ Dr Michael Crotty, a GP and obesity-medicine specialist, writes and broadcasts against the “eat less, move more” myth and the social-media framing of the drugs.¹⁹

On the patient side, the Irish Coalition for People Living with Obesity is the de-facto voice, with the important caveat that it discloses funding from the HSE and Novo Nordisk.²⁰ The one sizeable Irish journey creator, Paddy Cunningham (“A Dose of Paddy”), a former Biggest Loser contestant turned personal trainer, is candid and well-liked, but carries a clinic referral discount and Amazon affiliate links, the exact pattern the UK regulator sanctioned across the border.²¹

Germany, Austria and Switzerland

Germany has a mature medical-creator scene and a clear rule: the Heilmittelwerbegesetz bans advertising prescription-only medicines to the public, so the useful accounts are educators, not sellers.²²

Mai Thi Nguyen-Kim, the chemist behind maiLab and the television show MAITHINK X, is Germany’s most prominent science communicator, and her 2025 explainer testing the weight-loss injections against the evidence is the single best German-language starting point.²³ Among physician creators, Doc Felix publishes large-audience explainer and reaction videos across YouTube and Instagram, and the emergency physician Dr Carola Holzner (“Doc Caro”) brings a clinical, no-nonsense register to the same platforms.²⁴²⁵ For depth, Dr Matthias Riedl, medical director of the medicum Hamburg centre and a cast member of NDR’s long-running Die Ernährungs-Docs, has written a consumer book squarely on the after-the-injection question, Nie wieder dick nach der Abnehmspritze.²⁶

Germany also has an instructive counter-example. Dr Eckart von Hirschhausen, the physician and broadcaster, has spent much of his GLP-1 airtime warning that his own likeness is being used in AI deepfake advertisements selling fake weight-loss injections, a reminder that a familiar doctor’s face on a promotion is now itself a red flag.²⁷ On enforcement, a Munich court barred an online pharmacy from advertising the “Abnehmspritze” to consumers, and the German competition-standards body has issued disclosure warnings over undisclosed influencer promotion.²⁸

Austria and Switzerland are thinner. No Austrian creator with a verifiable following stood out; the public broadcaster ORF is the de-facto explainer.²⁹ In Switzerland, the medicines regulator Swissmedic openly worried that a “cult of thinness” on social media would drive demand when Wegovy launched, and the clearest social specimen is a cautionary journey account rather than a clinical one.³⁰

France

France has strong clinician and journalist voices and, tellingly, almost no named patient creators with a large following. The press covers the scene as a wave of anonymous “influenceuses” rather than profiling domestic stars, which is itself the finding.³¹

Prof Boris Hansel, a nutrition professor at Université Paris Cité, runs the public-health YouTube channel PuMS, the most established French medical explainer platform.³² Dr Jean-Michel Cohen, France’s most media-prominent nutritionist, publishes widely viewed videos dismantling the “natural Mounjaro” scams, though he also sells his own weight-loss programme, so read him as an interested party.³³ Dr Emmanuelle Lecornet-Sokol, an endocrinologist who heads the liberal endocrinologists’ federation, is the reliable press-and-radio explainer on who can actually access the drugs.³⁴

France’s standout book is journalist Fabrice Delaye’s Ozempic, la révolution de l’obésité, a Geneva-based long-form investigation of the science, the industry and access.³⁵ For the patient perspective, Anne-Sophie Joly of the national patient collective CNAO is the established advocate.³⁶ France also has the most concrete regulator story: the medicines agency ANSM has referred illegal online GLP-1 sellers to prosecutors since April 2025, and a 2026 France 2 investigation obtained a Mounjaro prescription online for under thirty euros in half an hour.³⁷³⁸

Spain

Spain’s most significant GLP-1 voice arrived by institutional appointment. Marián García, the pharmacist and science communicator known as Boticaria García, was chosen as Spain’s creator for the European Medicines Agency’s own anti-misinformation campaign against GLP-1 hype, which makes her the rare case of reach and official endorsement pointing the same way.³⁹

Among clinicians, Dr Víctor Bravo, an Almería endocrinologist, built a large Instagram audience on a deliberately contrarian message that daily steps beat reflexive injections.⁴⁰ Dr Cristóbal Morales, a Seville endocrinologist and spokesperson for the Spanish obesity society SEEDO, is the go-to press voice, and Dr Andreea Ciudin of the same society has publicly criticised pharmaceutical disease-awareness campaigns.⁴¹⁴² The dietitian Aitor Sánchez (“Mi Dieta Cojea”) is the trusted independent nutrition explainer.⁴³

Spain shows the commercial pressure clearly: the Swedish digital clinic Yazen runs an open, paid influencer-recruitment programme in Spain with no prescription-medicine disclaimer, and in 2026 the consumer group OCU had to report a fake “OzemPil” product that hijacked both Ozempic’s and OCU’s branding on Instagram.⁴⁴⁴⁵

Italy

Italy’s public conversation is led by senior academics and journalists more than by social creators. Prof Silvio Garattini, founder of the Mario Negri pharmacology institute, is the loudest sceptical voice, arguing against cosmetic use and calling on the medicines agency to run its own social campaigns.⁴⁶ Prof Rocco Barazzoni of the University of Trieste, president of the Italian obesity society, is the measured “revolutionary moment, inside lifestyle change” voice.⁴⁷

The essential Italian book is journalist Nicola Villa’s La cura miracolosa, billed as the first Italian book-length investigation of the drugs.⁴⁸ Among clinicians who publish under their own names, the endocrinologist Dott.ssa Laura Molteni produces practical YouTube guidance, though as always the follow-worthy signal is explanation, not a consultation funnel.⁴⁹ The patient organisation Amici Obesi, led by Iris Zani, is the established advocate and is running a national GLP-1 patient survey, with a podcast openly supported by Eli Lilly.⁵⁰

Italy’s regulator, AIFA, warned as early as March 2023 that any weight-management use of Ozempic was off-label, and its 2026 consumption data showed privately bought weight-management drugs up sharply.⁵¹ The media regulator AGCOM has also brought influencers formally under its rules, with a code of conduct that explicitly forbids promoting prescription medicines.⁵²

Netherlands and Belgium

The Low Countries produce some of Europe’s clearest clinical communicators. In the Netherlands, Prof Liesbeth van Rossum, an Erasmus MC obesity professor and co-author of the bestseller VET belangrijk, is the authoritative voice on why the drugs are a tool and not a miracle, and her co-author Dr Mariëtte Boon publishes in the same evidence-first register.⁵³⁵⁴ Academic explainers from Prof Gijs Goossens (Maastricht) and the Radboudumc “appropriate care” group separate the evidence from the hype well.⁵⁵⁵⁶

The Netherlands also offers the sharpest warning in Europe about where the line sits. In 2026 the medicines inspectorate IGJ fined several national newspapers and magazines for GLP-1 articles a court agreed had a promotional character, testimonials and before-and-after photos included.⁶ The lesson for readers is direct: in the strictest European market, even mainstream coverage that reads like a sales pitch can be unlawful, so the tone of what you follow is a signal in itself.

In Dutch-speaking Belgium, Prof Bart Van der Schueren of UZ Leuven, who chairs the Belgian obesity association, is the go-to public-broadcaster voice, alongside colleagues Prof Chantal Mathieu and the on-record sceptic Dr Patrik Vankrunkelsven.⁵⁷⁵⁸ The consumer organisation Testaankoop has been the most active watchdog, formally asking the regulator to act against pharmaceutical advertising for Wegovy and Mounjaro.⁵⁹

The Nordics

The Nordic pattern is distinctive: the “influencer” is usually a doctor-fronted telehealth clinic, and that is exactly the layer regulators are hitting.⁶⁰ The credible independent voices sit apart from it.

In Denmark, Novo Nordisk’s home market, the physicians behind the Radio Ligevægt podcast, Rasmus Køster-Rasmussen and Christian Vøhtz, publish evidence-based, anti-stigma content, and Køster-Rasmussen has publicly criticised his own home-market employer’s disease-awareness campaign.⁶¹ University of Copenhagen professors Signe Torekov and Tina Vilsbøll are the trusted research voices.⁶² Danish reporting has also shown Novo paying local doctors for awareness content, which is the kind of disclosure worth tracking.⁶³

In Sweden, Prof Ylva Trolle Lagerros of Karolinska stands out partly because she states plainly that she has no industry ties, notable after Swedish radio found a small group of company-paid doctors produced half the national expert commentary.⁶⁴ In Norway, Prof Jøran Hjelmesæth is the most prominent obesity expert, though he has been flagged for accepting Novo payments, and the writer Marianne Sæbø offers a thoughtful patient-adjacent perspective while explicitly not taking the drugs herself.⁶⁵⁶⁶ In Finland, Prof Kirsi Pietiläinen of the University of Helsinki is the clear authority, active across a personal podcast and national media.⁶⁷

The pan-European voices, and what the research says

Some of the most useful voices are not tied to one country. The European Association for the Study of Obesity is the de-facto scientific voice; its 2025 framework recommending semaglutide and tirzepatide as first-line treatment when substantial weight loss is needed is the reference document for the current moment.⁶⁸ The European Coalition for People living with Obesity is the patient umbrella.⁶⁹ The individual researchers already named, le Roux, Yeo, Sattar, cross borders through podcasts and books more than through any single feed.

The reason this guide steers away from the biggest social accounts is not snobbery. It is the evidence on content quality. A 2026 German study analysed 250 semaglutide posts across five platforms and found that ninety-eight per cent of user posts framed the drug for weight loss rather than diabetes, that gastrointestinal side effects were not mentioned at all on Instagram, and that a majority of before-and-after images were likely AI-modified.⁷⁰ A Spanish-language TikTok study scored the average video “poor” for reliability, with seventy-one per cent mentioning no risks.⁷¹ Across multiple analyses the pattern repeats: engagement and accuracy are unrelated, and the accounts with the most reach are the least likely to mention what can go wrong.⁷²

So the filter is simple. The voices worth your time name the side effects, state the limits, disclose their ties, and never ask you to use a code.